February 23, 2023 08:57 AM ESTUpdated February 24, 07:39 AM
Editor's note

Who are the young bio­phar­ma lead­ers mak­ing their mark in the in­dus­try? Nom­i­nate them for End­points' spe­cial re­port

Paul Schloesser

Associate Editor

Start­ing to­day, End­points News will be­gin ac­cept­ing nom­i­na­tions for our an­nu­al “20 Un­der 40” list.

Since 2020, End­points has pro­filed the biotech tal­ent …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
ENDPOINTS CAREERS

VP, Clinical Development / CMO / CDO‬ ‭ (Stealth Portfolio Company)

Autonomy Bio Inc.

San Francisco, CA 94107, USA

TRENDING NOW

FDA gives Ab­b­Vie ac­cel­er­at­ed ap­proval for an­ti­body-drug con­ju­gate in lung can­cer

RFK Jr. de­fends HHS staff cuts, re­or­ga­ni­za­tion plans in House, Sen­ate hear­ings

Ab­b­Vie dou­bles down on siR­NA with $335M up­front bet on ADARx

GSK to pay $1.2B up­front to snag Boston Phar­ma’s mid-stage MASH hope

RFK Jr. says his opin­ions of vac­cines are ‘ir­rel­e­vant.’ For­mer FDA chief Califf dis­agrees

No­vo turns to Septer­na for oral obe­si­ty med­i­cines in deal worth up to $2.2B

A service from the Financial Times